In contrast, when discussing tirzepatide vs retatrutide, it is notable that retatrutide is a novel triple agonist that activates GLP-1, GIP, and glucagon receptors
Fifth, previous CVOTs have suggested that the beneficial effects of GLP-1 RAs are primarily associated with long-acting agents such as liraglutide, semaglutide, and dulaglutide, rather than short-acting agents like exenatide and lixisenatide [17, 54, 56, 57, 68]
By continuing to use our site, you agree to our Terms of Use and Privacy Policy.
Effect of additional oral semaglutide vs sitagliptin on glycated haemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial